Zuranolone


Zuranolone is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor. The drug was developed as an improvement of allopregnanolone with high oral bioavailability and a biological half-life suitable for once-daily administration. As of October 2019, zuranolone is in phase III clinical trials for major depressive disorder, postpartum depression, and insomnia and is in phase II clinical studies for bipolar depression, essential tremor, and Parkinson's disease. It is also in the preclinical stage of development for dyskinesias.